Home/Rare Diseases/Epidermolysis Bullosa

Multi-System

Epidermolysis Bullosa

Also called EB, butterfly disease

Epidermolysis bullosa (EB) comprises a group of genetic blistering disorders caused by mutations affecting structural proteins anchoring the epidermis to the dermis at the dermal-epidermal junction. The condition presents with fragile, blistering skin that tears easily with minor trauma.

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Epidermolysis Bullosa

Gene therapy for epidermolysis bullosa is one of the most promising emerging therapies for genetic skin diseases. Clinical trials are evaluating ex vivo gene therapy (using patient's own keratinocytes genetically corrected ex vivo, then grafted back) and in vivo approaches.

Try Match Me →

About Epidermolysis Bullosa

Epidermolysis bullosa (EB) comprises a group of genetic blistering disorders caused by mutations affecting structural proteins anchoring the epidermis to the dermis at the dermal-epidermal junction. The condition presents with fragile, blistering skin that tears easily with minor trauma. Three major groups are recognized: EB simplex (usually mild, intraepidermal blistering), junctional EB (intermediate to severe, blistering at the basement membrane zone), and dystrophic EB (severe, subepidermal blistering with scarring). Patients with severe forms experience chronic, painful blistering; extensive scarring leading to contractures and loss of mobility; nail loss; and involvement of mucous membranes (oral, esophageal, GI tract), causing swallowing difficulties and nutritional compromise. Severe dystrophic EB patients have markedly reduced lifespan (median approximately 25-30 years) due to complications including infections, sepsis, malnutrition, and aggressive squamous cell carcinoma developing in scarred areas.

Common Symptoms

  • Blistering and erosions of skin from minimal trauma
  • Severe itching and pain
  • Scarring and contractures limiting mobility
  • Nail dystrophy and loss
  • Involvement of oral mucosa, esophagus, and GI tract
  • Increased risk of aggressive squamous cell carcinoma in severe types

Who It Affects

Multiple types with different genetic basis: EB simplex (usually mild), junctional EB (intermediate to severe), dystrophic EB (severe with extensive scarring). Autosomal dominant or recessive inheritance depending on type.

Getting Involved in Clinical Trials

Gene therapy for epidermolysis bullosa is one of the most promising emerging therapies for genetic skin diseases. Clinical trials are evaluating ex vivo gene therapy (using patient's own keratinocytes genetically corrected ex vivo, then grafted back) and in vivo approaches. PGEN-3 (an ex vivo gene therapy) has shown remarkable results in Phase 2 trials for recessive dystrophic EB, demonstrating durable healing and functional improvement. The Dystrophic Epidermolysis Bullosa Research Association (DEBRA) and patient organizations provide comprehensive trial information. If you have EB, discuss with your dermatologist about potential trial participation. Gene therapy represents potentially transformative treatment for selected EB types, offering hope for durable healing and improved quality of life.

Trusted Sources

Active Clinical Trials for Epidermolysis Bullosa

Finding trials for Epidermolysis Bullosa...

Related Multi-System Conditions

Multi-System

Sarcoidosis

Sarcoidosis is an inflammatory disease characterized by formation of granulomas (clusters of immune cells) in multiple o...

Multi-System

Tuberous Sclerosis

Tuberous sclerosis is an autosomal dominant genetic disorder caused by mutations in TSC1 or TSC2 genes, resulting in dys...

Multi-System

Progeria

Progeria is an extremely rare genetic disorder causing rapid aging in children. A single point mutation in the LMNA gene...